Testosterone in Women's HRT: the missing hormone

Ask a woman in perimenopause what she misses most, and you'll often hear the same list: libido, energy, mental sharpness, the ability to build muscle when she trains. Estrogen and progesterone matter, but they don't own that list. Testosterone does.

And yet testosterone is the hormone most women's HRT protocols leave out. Not because the science is missing — because the regulatory approvals are.

Women make testosterone too — and a lot of it

Here's the number that surprises most patients: across a woman's reproductive years, her ovaries and adrenals produce roughly three to four times more testosterone than estrogen by weight. Testosterone is quantitatively the most abundant biologically active sex steroid in the female body (Davis & Wahlin-Jacobsen, Lancet Diabetes Endocrinol, 2015).

Total testosterone in a healthy premenopausal woman typically runs 15–70 ng/dL. By the mid-40s, levels have often dropped by half from their 20s peak. By the postmenopausal years, they can be near the floor of assay detection.

That decline tracks with a specific symptom cluster:

• Low sexual desire and reduced arousal
• Blunted response to resistance training
• Persistent mental fog that estrogen replacement doesn't fully clear
• Reduced sense of drive or motivation
• Loss of lean mass despite adequate protein and training

These aren't vague complaints. They're the symptoms that show up in the trials.

What the evidence actually shows — in plain English

The strongest data is in hypoactive sexual desire disorder (HSDD) in postmenopausal women. A 2019 international consensus statement — endorsed by the Endocrine Society, the International Menopause Society, and eight other bodies — reviewed 46 randomized trials involving over 8,400 women and concluded that transdermal testosterone at physiologic doses meaningfully improves sexual desire, arousal, orgasm, and satisfaction (Davis et al., Climacteric, 2019).

Effect sizes were modest but real: roughly one additional satisfying sexual event per month over placebo, with parallel improvements in desire scores.

Beyond libido, the evidence gets thinner but still points in a direction. Small trials show improvements in lean body mass and bone density with physiologic testosterone. Cognitive and mood effects are inconsistent in the literature but frequently reported clinically.

What the consensus statement was careful about: it did not endorse testosterone for cognition, mood, energy, bone, or body composition as standalone indications — because the trials weren't designed to prove those endpoints, not because the trials disproved them.

Absence of evidence at trial scale is not evidence of absence at the individual level.

Why most clinics don't offer it — the real reason

There is no FDA-approved testosterone product for women in the United States. Zero. Every prescription written for a woman uses either a male product at a fractional dose or a compounded preparation.

That regulatory gap creates three problems for a typical clinic:

1. Liability optics. Prescribing off-label feels risky to clinicians trained to color inside the lines, even when the evidence supports it. 2. Dosing complexity. A male AndroGel pump delivers roughly 10x the dose a woman needs. Getting to the right physiologic range requires either careful fractional dosing or a compounded cream. 3. Monitoring skill. You have to know what to watch for, how to interpret female-range labs, and when to hold or adjust.

Most primary care and even most menopause clinics don't want to take that on. So they don't offer it, and women are told — incorrectly — that testosterone isn't for them.

{callout: The bottom line} Testosterone deficiency in women is real, treatable, and backed by international consensus for HSDD — but there's no FDA-approved female product, so most clinics avoid it entirely. That's a regulatory problem, not a clinical one.

What a reasonable protocol looks like — tuned to your numbers

The international consensus statement recommends transdermal delivery targeting premenopausal physiologic total testosterone levels — generally under 70 ng/dL. That's the ceiling, not a target.

Standard published approaches use transdermal testosterone cream at doses roughly one-tenth of typical male replacement. Titration is slow. Most women don't feel a subjective change for six to eight weeks, and full effect on desire endpoints in the trials took 12–24 weeks.

Injectable testosterone in women is controversial. It produces supraphysiologic peaks that most guidelines advise against, though some clinicians use very small doses successfully. Pellets are widely marketed and widely criticized for producing levels well above the physiologic range — the consensus statement specifically recommends against them.

The labs worth having in the conversation, if you choose to run bloodwork:

• Total testosterone (LC-MS/MS assay, not immunoassay — female-range immunoassays are notoriously unreliable)
• Free testosterone or SHBG to calculate it
• Estradiol and progesterone for full context
• DHEA-S, since adrenal precursor status matters
• CBC and lipids as safety baselines

A thorough workup would typically include those markers before starting, and periodic rechecks at 6–12 weeks after any dose change.

What to watch for — the honest trade-offs

At physiologic doses, side effects are uncommon and usually reversible. At supraphysiologic doses — which is what happens with pellets or male-dose products — you can see:

• Acne, oily skin
• Increased facial or body hair (hirsutism)
• Scalp hair thinning in genetically susceptible women
• Voice changes (rare but not fully reversible if it happens)
• Clitoral sensitivity changes

Long-term cardiovascular and breast cancer safety data at physiologic replacement doses are reassuring in the trials we have, but the trials we have are shorter than we'd like. The consensus statement is explicit: no signal for harm at physiologic dosing, but longer safety data is still needed.

That's a real trade-off, and it deserves an honest conversation rather than either dismissal or oversell.

Who's a candidate — and who isn't

The clearest indication is postmenopausal HSDD, particularly when estrogen replacement alone hasn't restored desire. Perimenopausal women with the same symptom cluster are increasingly treated by clinicians familiar with the evidence, even though the formal indication is post-menopause.

Reasonable candidates share a few features: symptoms that match the deficiency pattern, labs that support low physiologic status, no active hormone-sensitive cancer, and a willingness to monitor and titrate slowly.

Who should probably wait: women with active breast or endometrial cancer, uncontrolled cardiovascular disease, untreated sleep apnea, or acne and hirsutism that are already at their tolerance limit.

The bigger picture

Medicine takes 15–20 years to metabolize new evidence into standard practice. The consensus statement on testosterone for women came out in 2019. We're roughly halfway through that adoption curve.

In the meantime, women who read the evidence themselves are asking better questions than the clinics they walk into can answer. That's not a criticism of those clinics — it's a description of a gap.

If you're in that gap, the path forward is the same one that works for any HRT decision: get relevant labs run, understand your symptom pattern, work with a clinician who knows the female-specific dosing literature, and titrate slowly against how you actually feel and what your follow-up numbers show.

Testosterone isn't a miracle hormone. It's just the third one on the list — and for a lot of women, it's the one that's been missing.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.